SEARCH

SEARCH BY CITATION

References

  • 1
    Meyers RD, Adams W, Dardick K, Reinisch J, Von Reyn F, Renna T, McIntyre OR. The social and economic impact of hemophilia – a survey of 70 cases in Vermont and New Hampshire. Am J Public Health 1972; 62: 5305.
  • 2
    Szucs TD, Offner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia 1996; 2: 2117.
  • 3
    Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999; 5: 37885.
  • 4
    Naraine VS, Risebrough NA, Oh P, Blanchette VS, Lee S, Stain AM, Hedden D, Teitel JM, Feldman BM. Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique. Haemophilia 2002; 8: 11220.
  • 5
    Shapiro AD, Donfield SM, Lynn HS, Cool VA, Stehbens JA, Hunsberger SL, Tonetta S, Gomperts ED, Academic Achievement in Children with Hemophilia Study Group. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001; 108: E105.
  • 6
    Smit C, Rosendaal FR, Varekamp I, Brockeer-Vriends A, Van Dijck H, Suurmeijer TPBM, Briet E. Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972–85. BMJ 1989; 298: 2358.
  • 7
    Soucie JM, Cianfrini C, Janco RL, Kulkarni R, Hambleton J, Evatt B, Forsyth A, Geraghty S, Hoots K, Abshire T, Curtis R, Forsberg A, Huszti H, Wagner M, White GCI. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 246773.
  • 8
    Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244: 51522.
  • 9
    Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic vs. prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996; 129: 42431.
  • 10
    Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998; 79: 9327.
  • 11
    Globe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004; 10 (Suppl. 1): 6370.
  • 12
    Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 2532.
  • 13
    Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia 2004; 10 (Suppl. 4): 97104.
  • 14
    Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236: 3919.
  • 15
    Steen Carlsson K, Hojgard S, Glomstein A, Lethagen S, Schulman S, Tengborn L, Lindgren A, Berntorp E, Lindgren B. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 55566.
  • 16
    Manco-Johnson MJ, Abshire TC, Brown D, Buchanan GR, Cohen AR, DiMichele D, Hoots WK, Leissinger CA, McRedmond K, Nugent DJ, Shapiro AD, Thomas GA, Valentino LA, Riske B. Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency. Blood 2005; 106: 3.
  • 17
    Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 110913.
  • 18
    Van Den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, Van Der Bom JG, Nieuwenhuis HK. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 5615.
  • 19
    Ljung RCR. Prophylactic treatment in Sweden – overtreatment or optimal model? Haemophilia 1998; 4: 40912.
  • 20
    Szucs TD, Offner A, Kroner B, Giangrande P, Berntorp E, Schramm W. Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group. Haemophilia 1998; 4: 498501.
  • 21
    Ljung R, Aronis-Vournas S, Kurnik-Auberger K, Van Den Berg M, Chambost H, Claeyssens S, Van Geet C, Glomstein A, Hann I, Hill F, Kobelt R, Kreuz W, Mancuso G, Muntean W, Petrini P, Rosado L, Scheibel E, Siimes M, Smith O, Tusell J. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000; 6: 61924.
  • 22
    Blanchette VS, McReady M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9 (Suppl. 1): 1926.
  • 23
    Butler RB, McClure W, Wulff K. Practice patterns in haemophilia A therapy–a survey of treatment centres in the United States. Haemophilia 2003; 9: 54954.
  • 24
    Manco-Johnson MJ. Update on treatment regimens: prophylaxis vs. on-demand therapy. Semin Hematol 2003; 40 (Suppl. 3): 39.
  • 25
    Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99102.
  • 26
    Manco-Johnson MJ, Blanchette VS. North American prophylaxis studies for persons with severe haemophilia: background, rationale and design. Haemophilia 2003; 9 (Suppl. 1): 449.
  • 27
    Lusher JM. Assessment of response to treatment and design of clinical trials. Prog Clin Biol Res 1984; 150: 16779.
  • 28
    Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 17619.
  • 29
    Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000; 6: 64957.
  • 30
    Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30 (3 Suppl. 2): 36.
  • 31
    Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 1539.
  • 32
    Verbruggen B, Van Heerde W, Novakova I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 2002; 88: 3624.
  • 33
    Kern M, Blanchette V, Stain AM, Einarson TR, Feldman BM. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr 2004; 145: 62834.
  • 34
    Fischer K, Van Der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, Grobbee DE, Van Den Berg HM. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7: 44652.
  • 35
    Fischer K, Van Der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, De Kleijn P, Grobbee DE, Van Den Berg M. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood. 2002; 99: 233741.
  • 36
    Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? – the German experience. Haemophilia 1998; 4: 4137.
  • 37
    Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 9738.
  • 38
    Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients – a long-term follow-up. J Intern Med 1997; 241: 395400.
  • 39
    Yee TT, Beeton K, Griffioen A, Harrington C, Miners A, Lee CA, Brown SA. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 7682.
  • 40
    Chehab N. A Review of Coagulation Products Used in the Treatment of Hemophilia. Pharmacotherapy Update 2002 [cited May 20 2005]; Available from: http://www.clevelandclinicmeded.com/medical_info/pharmacy/julyaugust2002/coagulation.htm#table1.
  • 41
    Tuddenham EG, Laffan M. Purified factor VIII. BMJ 1995; 311: 4656.
  • 42
    Kavakli K, Nisli G, Aydinok Y, Oztop S, Cetingul N, Aydogdu S, Yalman O. Prophylactic therapy for hemophilia in a developing country, Turkey. Pediatr Hematol Oncol 1997; 14: 1519.
  • 43
    Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998; 4: 47480.
  • 44
    Price VE, Carcao M, Connolly B, Chait P, Daneman A, Temple M, Stain AM, Sung L, Al-Tralbosi H, Blanchette VS. A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia. J Thromb Haemost 2004; 2: 73742.